Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 15/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16597548 | 0.99 | BTK (0.51) | BTKCHEK1SCN9AHCRTR1HCRTR2 | |
| SCHEMBL16613215 | 0.94 | BTK (0.55) | BTKCHEK1SCN9A | |
| SCHEMBL16613213 | 0.94 | BTK (0.56) | BTKCHEK1SCN9AHCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL16597746 | 0.93 | BTK (0.54) | BTKCHEK1SCN9A | |
| Hydrochloric Acid SCHEMBL16597535 | 0.93 | BTK (0.55) | BTKCHEK1SCN9AHCRTR1HCRTR2 | |
| SCHEMBL18017508 | 0.84 | PARP1 (0.39) | CHEK1HCRTR1HCRTR2GABRA1 | |
| SCHEMBL8625987 | 0.79 | HCRTR1 (0.43) | BTKHCRTR1HCRTR2 | |
| SCHEMBL28131821 | 0.79 | BTK (0.60) | BTK | |
| Water SCHEMBL8628635 | 0.78 | HCRTR1 (0.43) | BTKHCRTR1HCRTR2 | |
| Bromide SCHEMBL8625322 | 0.78 | HCRTR1 (0.43) | BTKHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | Guangzhou Innocare Pharma Tech Co., Ltd (CN) | 2023-12-12 | — | — | US | disclosed |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2022-09-22 | — | — | US | disclosed |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2019-09-12 | — | — | US | disclosed |
| US-10301297-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-08-09 | — | — | US | disclosed |
| US-9951056-B2 | Substituted nicotinamide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20160237075-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | GUANGZHOU INNOCARE PHARMA TECH CO., LTD. (CN) | 2016-08-18 | — | — | US | disclosed |
| WO-2015048662-A2 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | X-RX DISCOVERY, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237075-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | BTK 1/4885CHEK1 396/4885SCN9A 922/4885 |
| US-20190276446-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | BTK 1/4885CHEK1 396/4885SCN9A 922/4885 |
| US-20180222897-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE | BTK, SYK, LYN | BTK 1/4885CHEK1 396/4885SCN9A 922/4885 |
| US-11345695-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | BTK 1/4885CHEK1 396/4885SCN9A 922/4885 |
| US-10301297-B2 | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | BTK, SYK, LYN | BTK 1/4885CHEK1 396/4885SCN9A 922/4885 |
| US-20220298153-A1 | SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK FOR TREATING CANCER | BTK, SYK, LYN | BTK 1/4885CHEK1 436/4885SCN9A 846/4885 |
| US-11840513-B2 | Substituted nicotinimide inhibitors of BTK for treating cancer | BTK, SYK, LYN | BTK 1/4885CHEK1 436/4885SCN9A 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.